1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NovoCure Limited
  6. Summary
    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
74.70 USD   +0.88%
05/16NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT
05/16HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT
05/13Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
66.7(c) 71.69(c) 69.73(c) 74.05(c) 74.7(c) Last
520 101 427 407 472 038 714 181 589 813 Volume
+2.24% +7.48% -2.73% +6.20% +0.88% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -129x
Yield 2022 -
Sales 2023 592 M - -
Net income 2023 -62,0 M - -
Net Debt 2023 240 M - -
P/E ratio 2023 -131x
Yield 2023 -
Capitalization 7 813 M 7 813 M -
EV / Sales 2022 14,7x
EV / Sales 2023 13,6x
Nbr of Employees 1 167
Free-Float 86,5%
More Financials
Company
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through... 
More about the company
Ratings of NovoCure Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about NOVOCURE LIMITED
05/16NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT
05/16HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT
05/13Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight ..
MT
04/28NovoCure's Q1 Net Loss Flat, Revenue Rises
MT
04/28TRANSCRIPT : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28NOVOCURE : Q1 Earnings Snapshot
AQ
04/28NOVOCURE : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K
PU
04/28Earnings Flash (NVCR) NOVOCURE Reports Q1 Loss $-0.04, vs. Street Est of $-0.19
MT
04/28Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $137.5M, vs. Street Est of $134.3M
MT
04/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
04/28Novocure Reports First Quarter 2022 Financial Results
BU
04/28NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/19Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
BU
04/13NOVOCURE LTD : Change in Directors or Principal Officers, Financial Statements and Exhibit..
AQ
04/13Novocure Limited Announces Resignation of Sherilyn McCoy from the Board of Directors
CI
More news
News in other languages on NOVOCURE LIMITED
05/16Les actions de NovoCure augmentent après que HC Wainwright ait initié une couverture à ..
04/28La perte nette de NovoCure au 1er trimestre est stable, les revenus augmentent
04/28Earnings Flash (NVCR) NOVOCURE affiche un chiffre d'affaires de 137,5 millions de dolla..
04/28NovoCure Limited annonce ses résultats financiers pour le premier trimestre terminé le ..
04/13Novocure Limited annonce la démission de Sherilyn McCoy du conseil d'administration
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 74,70 $
Average target price 101,44 $
Spread / Average Target 35,8%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-0.51%7 813
MASIMO CORPORATION-51.71%7 839
GETINGE AB-27.61%7 819
SHOCKWAVE MEDICAL, INC.-11.25%5 665
PENUMBRA, INC.-50.59%5 349
IRAY TECHNOLOGY COMPANY LIMITED-22.53%4 173